<div id="readability-page-1"><div> RTI opioid treatment program-level measures of retention highlight opportunities for quality improvementRESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 /PRNewswire/ -- A new study published in JAMA Network Open and authored by experts at RTI International, an independent scientific research institute, has found that many opioid treatment programs (OTPs) across the U.S. are struggling to keep patients engaged. According to the study, at typical opioid treatment programs, 61% of Medicaid patients remained in care beyond the first month, but, among the bottom quarter of programs, only 40% remained in treatment for at least one month.&#34;For opioid use disorder, treatment retention is one of the strongest predictors of recovery and survival for patients experiencing opioid use disorder,&#34; said lead author Tami Mark, Ph.D., a Distinguished Fellow at RTI. &#34;This new measure offers OTPs a consistent benchmark that shows how their retention rates align with national patterns, enabling programs to pinpoint strengths, isolate gaps and prioritize targeted improvements.&#34;RTI researchers created case-mix adjusted retention measures using Medicaid claims data from 2018 to 2023. In 2023, the measures included more than 1,100 OTPs, 432,000 treatment episodes, and 261,000 patients.The measures reveal a wide variation in OTPs' retention rates:<ul><li>OTPs in the top 75% retained 73.5% of participants for 30 days, compared with 40.9% in the bottom 25%.</li><li>At 90 days, top OTPs retained 54.8%, while bottom–quartile programs retained 22.2%.</li><li>At 180 days, retention was 40.5% in the top group and 11.4% in the bottom group.</li></ul>RTI researchers Dylan DeLisle, MPH, Chelsea Katz, Ph.D.; William Dowd, Ph.D.; Daniel Barch, Ph.D.; Marianne Kluckman, MPH, also contributed to the study, which was supported by the NIH HEAL Initiative.Read the full studyLearn more about RTI's substance use researchAbout RTI InternationalRTI International is an independent scientific research institute dedicated to improving the human condition. Our vision is to address the world's most critical problems with technical and science-based solutions in pursuit of a better future. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across social, statistical, data, and laboratory sciences, engineering, and other technical disciplines to solve the world's most challenging problems. For more information, visit www.rti.org.Media Contact: RTI International Media Relations 408153@email4pr.com 919-541-7300 <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMyZzbj1QSDcwMDMz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMyZzbj1QSDcwMDMz"/> View original content:https://www.prnewswire.com/news-releases/new-quality-measures-reveal-wide-variation-in-opioid-treatment-programs-medicaid-patient-retention-rates-302669211.htmlSOURCE RTI International</div></div>

RTI International 在 JAMA Network Open 上发布的一项研究揭示了美国阿片类药物治疗项目（OTPs）中医疗补助患者保留率的显著差异。研究表明，仅有 61% 的医疗补助患者在第一个月后继续接受治疗，而排名最低的 25% 的项目仅保留了 40% 的患者。该研究强调了治疗保留作为阿片类药物使用障碍患者康复和生存的预测指标的重要性。研究结果建议，OTPs 可以利用这些基准来识别患者参与度改善的领域

New Quality Measures Reveal Wide Variation in Opioid Treatment Programs' Medicaid Patient Retention Rates

MorningStar

医疗业 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - Vanguard

Iovance生物治疗

Invesco S&P 500 Equal Weight Health Care ETF

阿尔凯默斯

医药突破 ETF - ALPS

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

Elevance Health

Molina医疗

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

Phibro Animal Health

标普全球医疗股指数 ETF - iShares

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

康西哥

Hookipa Pharma

2 倍做空卫生保健 ETF - ProShares

联合健康

阿卡迪亚医疗保健

西维斯

Leverage Shares 2X Long UNH Daily ETF

标普医疗保健服务 ETF - SPDR

美国医疗保健供应商 ETF - iShares

生物科技 ETF - VanEck Vectors

Indivior

新的质量措施揭示了阿片类药物治疗项目中医疗补助患者保留率的显著差异